In a simulated study, exposure to and maximum blood concentrations of two selective serotonin reuptake inhibitors (SSRIs) - commonly used to treat anxiety and depression in adolescents—differed depending on whether the teens modeled were poor, normal, rapid, or ultra-rapid metabolizers of the SSRIs. Caused by differences in the gene coding for cytochrome P4502C19 (CYP2C19), this information could inform SSRI dosing to optimize efficacy of the medications and minimize adverse effects, as reported in an article published in the Journal of Child and Adolescent Psychopharmacology.
* This article was originally published here
